New effort to standardize cardiovascular care in Mexico, address gaps in care

DALLAS and MEXICO CITY, June 2, 2022 — In Mexico, 56.1% of adults have excessive ranges of LDL-C or unhealthy ldl cholesterol[1], thought of the primary threat issue for heart problems and explanation for atherosclerotic heart problems (ASCVD), a buildup of fat, ldl cholesterol and different substances contained in the arteries and on their partitions, which might trigger narrowing of the arteries, obstructing blood move. The American Coronary heart Affiliation®, the world’s main drive for longer, more healthy lives, has launched a brand new implementation science program in Mexico targeted on bettering look after sufferers with ASCVD, also referred to as atherosclerosis, made doable with funding by Novartis. 

The American Coronary heart Affiliation implementation science initiative identifies, develops and integrates medical finest practices and workflows into the routines of the healthcare professionals. Standardizing the analysis and remedy of cardiovascular illnesses is a key tenet of the standard enchancment initiatives the American Coronary heart Affiliation implements world wide. 

Presently, solely 2/3 of the inhabitants in Mexico with ASCVD obtain any kind of remedy.[2] Of them, lower than half are handled and of those, 45% are uncontrolled and don’t adhere to remedy.[3]

“Lowering LDL-c levels of cholesterol in a constant and sustainable method is vital to stopping atherosclerosis and with it, the problems brought on by this illness equivalent to myocardial infarction, coronary heart failure and stroke,” mentioned Jorge Saucedo, M.D. MBVA, FAHA, volunteer knowledgeable for the American Coronary heart Affiliation and professor and division chief for the Coronary heart and Vascular Middle at Froedtert Hospital for the Medical School of Wisconsin. “The American Coronary heart Affiliation {and professional} societies just like the Mexican Society of Cardiology and ANCAM (Nationwide Affiliation of Cardiologists of Mexico) are working collectively to convene private and non-private well being establishments to comprehensively fight this illness.”

The initiative will educate the proper software of high quality enchancment methods, present hospital session and knowledge assessment and generate proof that helps to spotlight each the successes and the present and future challenges in cardiovascular care. Leveraging its 20+ years of expertise in high quality enchancment, the American Coronary heart Affiliation will likely be using its U.S. primarily based Get With The Pointers registry for knowledge assortment, furthering growth alternatives for benchmarking and analysis.

“By supporting this initiative, we goal to detect and apply appropriate remedy for this illness and sluggish its development,” commented Viviam Ubiarco, M.D., chief science officer of Novartis Mexico. “The influence of those actions will likely be mirrored within the discount of coronary heart assaults, hospitalizations, and deaths, which in lots of circumstances represents a excessive value to the well being care system and impacts the standard of lifetime of the affected person.”

Giselle Roman, M.D., therapeutic-area head of cardiovascular illnesses in Novartis, added, “By educating the inhabitants and creating a way of urgency for well being serving establishments, we will enhance the remedy of cardiovascular illnesses, an invisible pandemic in Mexico.”

In regards to the American Coronary heart Affiliation

The American Coronary heart Affiliation is a relentless drive for a world of longer, more healthy lives. We’re devoted to making sure equitable well being in all communities. By collaboration with quite a few organizations, and powered by thousands and thousands of volunteers, we fund revolutionary analysis, advocate for the general public’s well being and share lifesaving assets. The Dallas-based group has been a number one supply of well being info for almost a century. Join with us on coronary, Fb, Twitter or by calling 1-800-AHA-USA1.   

Acerca de la American Coronary heart Affiliation

La American Coronary heart Affiliation es una fuerza incansable para un mundo de vidas más largas y saludables. Nos dedicamos a asegurar una salud equitativa en todas las comunidades. A través de la colaboración con numerosas organizaciones, e impulsados por millones de voluntarios, financiamos la investigación innovadora, abogamos por la salud pública y compartimos recursos que salvan vidas. La organización con sede en Dallas ha sido una fuente líder de información de salud durante casi un siglo. Conéctese con nosotros en coronary, Fb, Twitter o llamando al 1-800-AHA-USA1.

Acerca de Novartis

En Novartis estamos reimaginando la medicina para mejorar y extender la vida de las personas. Como empresa líder mundial en medicamentos, utilizamos ciencia innovadora y tecnologías digitales para crear tratamientos transformadores en áreas de gran necesidad médica. En nuestra búsqueda por encontrar nuevos medicamentos, clasificamos constantemente entre las principales empresas del mundo que invierten en investigación desarrollo. Nuestros productos llegan a más de 750 millones de personas en todo el mundo y estamos en nuestro camino por encontrar formas innovadoras de ampliar el acceso a nuestros últimos tratamientos. Alrededor de 109,000 personas de más de 145 nacionalidades trabajan en Novartis. Para mayor información visita 

Novartis Mexico on social media. Observe us: Twitter @novartismexico, Fb – @novartismexico, LinkedIn – Novartis México

Spanish information launch

Media Contacts: 

American Coronary heart Affiliation: Karen Springs, 214-706-4831, [email protected]

Novartis: Eunice Barrientos, Communications Supervisor, [email protected]

American Coronary heart Affiliation: For Public Inquiries: 1-800-AHA-USA1 (242-8721) or coronary and

[2] Cardoso-Saldaña G, de la Peña-Díaz A, Zamora-González J. et al. Ethnicity and lipoprotein(a) polymorphism in Native Mexican populations. Annals of Human Biology, March–April 2006; 33(2): 202–212

[3] Cardoso-Saldaña G, de la Peña-Díaz A, Zamora-González J. et al. Ethnicity and lipoprotein(a) polymorphism in Native Mexican populations. Annals of Human Biology, March–April 2006; 33(2): 202–212

Related Articles

Back to top button